Note 9 - Equipment, Net |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment Disclosure [Text Block] |
NOTE 9: EQUIPMENT, NET
Equipment balance is as follows:
Depreciation expense was $46 and $12 for the years ended December 31, 2025 and 2024, respectively.
During the reporting period, management evaluated the Company’s capitalized medical equipment costs for indicators of impairment in accordance with ASC 360-10, Impairment or Disposal of Long-Lived Assets. The review was prompted by a change in strategic direction resulting from the acquisition of Evoke Neuroscience and its hardware offering.
Accordingly, the Company recognized an impairment loss of $99 during the period ended December 31, 2025. This charge was recorded within “Impairment of assets” on the statement of operations, reducing the carrying value of the equipment asset to
Medical equipment subject to operating leases includes hardware leased to customers as part of the Company’s products and services offerings.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||